423 related articles for article (PubMed ID: 30909402)
1. Between Innate and Adaptive Immune Responses: NKG2A, NKG2C, and CD8⁺ T Cell Recognition of HLA-E Restricted Self-Peptides Acquired in the Absence of HLA-Ia.
Pump WC; Kraemer T; Huyton T; Hò GT; Blasczyk R; Bade-Doeding C
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909402
[TBL] [Abstract][Full Text] [Related]
2. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells.
Pietra G; Romagnani C; Moretta L; Mingari MC
Curr Pharm Des; 2009; 15(28):3336-44. PubMed ID: 19860683
[TBL] [Abstract][Full Text] [Related]
3. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer.
Llano M; Lee N; Navarro F; García P; Albar JP; Geraghty DE; López-Botet M
Eur J Immunol; 1998 Sep; 28(9):2854-63. PubMed ID: 9754572
[TBL] [Abstract][Full Text] [Related]
4. A structural basis for antigen presentation by the MHC class Ib molecule, Qa-1b.
Zeng L; Sullivan LC; Vivian JP; Walpole NG; Harpur CM; Rossjohn J; Clements CS; Brooks AG
J Immunol; 2012 Jan; 188(1):302-10. PubMed ID: 22131332
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues.
Wada H; Matsumoto N; Maenaka K; Suzuki K; Yamamoto K
Eur J Immunol; 2004 Jan; 34(1):81-90. PubMed ID: 14971033
[TBL] [Abstract][Full Text] [Related]
6. Association of CD94/NKG2A, CD94/NKG2C, and its ligand HLA-E polymorphisms with Behcet's disease.
Seo J; Park JS; Nam JH; Bang D; Sohn S; Lee ES; Park KS
Tissue Antigens; 2007 Oct; 70(4):307-13. PubMed ID: 17767552
[TBL] [Abstract][Full Text] [Related]
7. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells.
Gumá M; Busch LK; Salazar-Fontana LI; Bellosillo B; Morte C; García P; López-Botet M
Eur J Immunol; 2005 Jul; 35(7):2071-80. PubMed ID: 15940674
[TBL] [Abstract][Full Text] [Related]
8. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells.
Brooks AG; Borrego F; Posch PE; Patamawenu A; Scorzelli CJ; Ulbrecht M; Weiss EH; Coligan JE
J Immunol; 1999 Jan; 162(1):305-13. PubMed ID: 9886400
[TBL] [Abstract][Full Text] [Related]
9. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
[TBL] [Abstract][Full Text] [Related]
10. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence.
Petrie EJ; Clements CS; Lin J; Sullivan LC; Johnson D; Huyton T; Heroux A; Hoare HL; Beddoe T; Reid HH; Wilce MC; Brooks AG; Rossjohn J
J Exp Med; 2008 Mar; 205(3):725-35. PubMed ID: 18332182
[TBL] [Abstract][Full Text] [Related]
11. HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire.
Lauterbach N; Wieten L; Popeijus HE; Voorter CE; Tilanus MG
Hum Immunol; 2015 Aug; 76(8):578-86. PubMed ID: 26382247
[TBL] [Abstract][Full Text] [Related]
12. NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.
Battin C; Kaufmann G; Leitner J; Tobias J; Wiedermann U; Rölle A; Meyer M; Momburg F; Steinberger P
Immunology; 2022 Aug; 166(4):507-521. PubMed ID: 35596615
[TBL] [Abstract][Full Text] [Related]
13. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes.
Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F
Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for NKG2A/CD94 recognition of HLA-E.
Kaiser BK; Pizarro JC; Kerns J; Strong RK
Proc Natl Acad Sci U S A; 2008 May; 105(18):6696-701. PubMed ID: 18448674
[TBL] [Abstract][Full Text] [Related]
15. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2.
Miller JD; Weber DA; Ibegbu C; Pohl J; Altman JD; Jensen PE
J Immunol; 2003 Aug; 171(3):1369-75. PubMed ID: 12874227
[TBL] [Abstract][Full Text] [Related]
17. NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.
Hò GT; Celik AA; Huyton T; Hiemisch W; Blasczyk R; Simper GS; Bade-Doeding C
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575403
[TBL] [Abstract][Full Text] [Related]
18. Expression of NK cell receptors on decidual T cells in human pregnancy.
Tilburgs T; van der Mast BJ; Nagtzaam NM; Roelen DL; Scherjon SA; Claas FH
J Reprod Immunol; 2009 Jun; 80(1-2):22-32. PubMed ID: 19394706
[TBL] [Abstract][Full Text] [Related]
19. Nonameric Peptide Orchestrates Signal Transduction in the Activating HLA-E/NKG2C/CD94 Immune Complex as Revealed by All-Atom Simulations.
Prašnikar E; Perdih A; Borišek J
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206395
[TBL] [Abstract][Full Text] [Related]
20. The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity.
Sullivan LC; Clements CS; Rossjohn J; Brooks AG
Tissue Antigens; 2008 Nov; 72(5):415-24. PubMed ID: 18946929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
